You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Claims for Patent: 5,512,570


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,512,570
Title: Treatment of emesis with morpholine tachykinin receptor antagonists
Abstract:Substituted heterocycles of the structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, emesis and nausea.
Inventor(s): Dorn; Conrad P. (Plainfield, NJ), MacCoss; Malcolm (Freehold, NJ), Hale; Jeffrey J. (Westfield, NJ), Mills; Sander G. (Woodbridge, NJ)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:08/450,507
Patent Claims: 1. A method for the treatment or prevention of emesis in a mammal in need thereof which comprises the administration to the mammal of an effective amount of a compound of the formula I: ##STR11## or a pharmaceutically acceptable salt thereof, wherein: R.sup.2 and R.sup.3 are independently selected from the group consisting of:

(1) hydrogen,

(2) C.sub.1-6 alkyl, unsubstituted or substituted with one or ed from:

(a) hydroxy,

(b) oxo,

(c) C.sub.1-6 alkoxy,

(d) phenyl --C.sub.1-3 alkoxy,

(e) phenyl,

(f) --CN,

(g) halo,

(h) --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are independently selected from:

(i) hydrogen,

(ii) C.sub.1-6 alkyl,

(iii) hydroxy --C.sub.1-6 alkyl, and

(iv) phenyl,

(i) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(j) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(k) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(l) --COR.sup.9, wherein R.sup.9 is as defined above, and

(m) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above;

(3) C.sub.2-6 alkenyl, unsubstituted or substituted with one or more of the substituent(s) selected from:

(a) hydroxy,

(b) oxo,

(c) C.sub.1-6 alkoxy,

(d) phenyl --C.sub.1-3 alkoxy,

(e) phenyl,

(f) --CN,

(g) halo,

(h) --CONR.sup.9 R.sup.10 wherein R.sup.9 and R.sup.10 are as defined above,

(i) --COR.sup.9 wherein R.sup.9 is as defined above,

(j) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above;

(4) C.sub.2-6 alkynyl;

(5) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from:

(a) hydroxy,

(b) C.sub.1-6 alkoxy,

(c) C.sub.1-6 alkyl,

(d) C.sub.2-5 alkenyl,

(e) halo,

(f) --CN,

(g) --NO.sub.2,

(h) --CF.sub.3,

(i) --(CH.sub.2).sub.m -NR.sup.9 R.sup.10, wherein m, R.sup.9 and R.sup.10 are as defined above,

(j) --NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(k) --NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as de fined above,

(l) --CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(m) --CO.sub.2 NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(n) --COR.sup.9, wherein R.sup.9 is as defined above;

(o) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above;

and, alternatively, the groups R.sup.2 and R.sup.3 are joined together to form a carbocyclic ring selected from the group consisting of:

(a) cyclopentyl,

(b) cyclohexyl,

(c) phenyl,

and wherein the carbocyclic ring is unsubstituted or substituted with one or more substituents selected from:

(i) C.sub.1-6 alkyl,

(ii) C.sub.1-6 alkoxy,

(iii) --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(iv) halo, and

v) trifluoromethyl;

and, alternatively, the groups R.sup.2 and R.sup.3 are joined together to form a heterocyclic ring selected from the group consisting of:

(a) pyrrolidinyl,

(b) piperidinyl,

(c) pyrrolyl,

(d) pyridinyl,

(e) imidazolyl,

(f) furanyl,

(g) oxazolyl,

(h) thienyl, and

(i) thiazolyl,

and wherein the heterocyclic ring is unsubstituted or substituted with one or more substituent(s) selected from:

(i) C.sub.1-6 alkyl,

(ii) oxo,

(iii) C.sub.1-6 alkoxy,

(iv) -NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(v) halo, and

(vi) trifluoromethyl:

R.sup.6, R.sup.7 and R.sup.8 are independently selected from the group consisting of:

(1) hydrogen;

(2) C.sub.1-6 alkyl unsubstituted or substituted with one or more of the substituents selected from:

(a) hydroxy,

(b) oxo,

(c) C.sub.1-6 alkoxy,

(d) phenyl -C.sub.1-3 alkoxy,

(e) phenyl,

(f) -CN,

(g) halo,

(h) -NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(i) -NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(j) -NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(k) -CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(l) -COR.sup.9, wherein R.sup.9 is as defined above, and

(m) -CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above;

(3) C.sub.2-6 alkenyl, unsubstituted or substituted with one or more of the substituent(s) selected from:

(a) hydroxy,

(b) oxo,

(c) C.sub.1-6 alkoxy,

(d) phenyl -C.sub.1-3 alkoxy,

(e) phenyl,

(f) -CN,

(g) halo,

(h) -CONR.sup.9 R.sup.10 wherein R.sup.9 and R.sup.10 are as defined above,

(i) -COR.sup.9 wherein R.sup.9 is as defined above,

(j) -CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above;

(4) C.sub.2-6 alkynyl;

(5) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from:

(a) hydroxy,

(b) C.sub.1-6 alkoxy,

(c) C.sub.1-6 alkyl,

(d) C.sub.2-5 alkenyl,

(e) halo,

(f) -CN,

(g) -NO.sub.2,

(h) -CF.sub.3,

(i) -(CH.sub.2).sub.m -NR.sup.9 R.sup.10, wherein m, R.sup.9 and R.sup.10 are as defined above,

(j) -NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(k) -NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(l) -CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(m) -CO.sub.2 NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(n) -COR.sup.9, wherein R.sup.9 is as defined above;

(o) -CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above;

(6) halo,

(7) -CN,

(8) -CF.sub.3,

(9) -NO.sub.2,

(10) -SR.sup.14, wherein R.sup.14 is hydrogen or C.sub.1-5 alkyl,

(11) -SOR.sup.14, wherein R.sup.14 is as defined above,

(12) -SO.sub.2 R.sup.14, wherein R.sup.14 is as defined above,

(13) NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(14) CONR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(15) NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(16) NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(17) hydroxy,

(18) C.sub.1-6 alkoxy,

(19) COR.sup.9, wherein R.sup.9 is as defined above,

(20) CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above,

(21) 2-pyridyl,

(22) 3-pyridyl,

(23) 4-pyridyl,

(24) 5-tetrazolyl,

(25) 2-oxazolyl, and

(26) 2-thiazolyl;

R.sup.11, R.sup.12 and R.sup.13 are independently selected from the definitions of R.sup.6, R.sup.7 and R.sup.8, or -OX;

A is selected from the group consisting of:

(1) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from:

(a) hydroxy,

(b) oxo,

(c) C.sub.1-6 alkoxy,

(d) phenyl -C.sub.1-3 alkoxy,

(e) phenyl,

(f) -CN,

(g) halo, wherein halo is fluoro, chloro, bromo or iodo,

(h) -NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(i) -NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(j) -NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above.

(k) -CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(l) -COR.sup.9, wherein R.sup.9 is as defined above, and

(m) -CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above;

(2) C.sub.2-6 alkenyl, unsubstituted or substituted with one or more of the substituent(s) selected from:

(a) hydroxy,

(b) oxo,

(c) C.sub.1-6 alkoxy,

(d) phenyl -C.sub.1-3 alkoxy,

(e) phenyl,

(f) -CN,

(g) halo,

(h) -CONR.sup.9 R.sup.10 wherein R.sup.9 and R.sup.10 are as defined above,

(i) -COR.sup.9 wherein R.sup.9 is as defined above, and

(j) -CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above; and

(3) C.sub.2-6 alkynyl;

B is a heterocycle, wherein the heterocycle is selected from the group consisting of: ##STR12## and wherein the heterocycle is substituted in addition to -X with one or more substituent(s) selected from:

(i) hydrogen;

(ii) C.sub.1-6 alkyl, unsubstituted or substituted with halo. -CF.sub.3, -OCH.sub.3, or phenyl,

(iii) C.sub.1-6 alkoxy,

(iv) OXO,

(v) hydroxy,

(vi) thioxo,

(vii)-SR.sup.9, wherein R.sup.9 is as defined above,

(viii) halo,

(ix) cyano,

(x) phenyl,

(xi) trifluoromethyl,

(xii) -(CH.sub.2).sub.m -NR.sup.9 R.sup.10, wherein m is 0, 1 or 2, and R.sup.9 and R.sup.10 are as defined above,

(xiii) -NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(xiv) -CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(xv) -CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above, and

(xvi) -(CH.sub.2).sub.m -OR.sup.9, wherein m and R.sup.9 are as defined above;

p is 0 or 1;

X is selected from:

(a) -PO(OH)O-. M.sup.+, wherein M.sup.+ is a pharmaceutically acceptable monovalent counterion,

(b) -PO(O.sup.-).sub.2.2M.sup.+,

(c) -PO(O.sup.-).sub.2.D.sup.2 +, wherein D.sup.2+ is a pharmaceutically acceptable divalent counterion,

(d) -CH(R.sup.4)-PO(OH)O-.sup.-. M.sup.+, wherein R.sup.4 is hydrogen or C.sub.1-3 alkyl,

(e) -CH(R.sup.4)-PO(O.sup.-).sub.2.2M.sup.+,

(f) -CH(R.sup.4)-PO(O.sup.-).sub.2.D.sup.2+,

(g) -SO.sub.3 -.M.sup.+,

(h) -CH(R.sup.4)-SO.sub.3 -.M.sup.30 ,

(i) -CO-CH.sub.2 CH.sub.2 -CO.sub.2 -.M.sup.+,

(j)-CH(CH.sub.3)-O-CO-R.sup.5, wherein R.sup.5 is selected from the group consisting of: ##STR13## (k) hydrogen, with the proviso that is p is 0 and none of R.sup.11, R.sup.12 or R.sup.13 are -OX, then X is other than hydrogen;

Y is selected from the group consisting of:

(1) a single bond,

(2) -O-,

(3) -S-,

(4) -CO-,

(5) -CH.sub.2 -,

(6) -CHR.sup.15 -, and.

(7) -CR.sup.15 R.sup.16 -, wherein R.sup.15 and R.sup.16 are independently selected from the group consisting of:

(a) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from:

(i) hydroxy,

(ii) OXO,

(iii) C.sub.1-6 alkoxy,

(iv) phenyl -C.sub.1-3 alkoxy,

(v) phenyl,

(vi) -CN,

(vii) halo,

(viii) -NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(ix) -NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(x) -NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(xi) -CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(xii) -COR.sup.9, wherein R.sup.9 is as defined above, and

(xiii) -CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above;

(b) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from:

(i) hydroxy,

(ii) C.sub.1-6 alkoxy,

(iii) C.sub.1-6 alkyl,

(iv) C.sub.2-5 alkenyl,

(v) halo,

(vi) -CN,

(vii) -NO.sub.2,

(viii) -CF.sub.3,

(ix) -(CH.sub.2).sub.m -NR.sup.9 R.sup.10, wherein m, R.sup.9 and R.sup.10 are as defined above,

(x) -NR.sup.9 COR.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(xi) -NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(xii) -CONR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(xiii) -CO.sub.2 NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are as defined above,

(xiv) -COR.sup.9, wherein R.sup.9 is as defined above, and

(xv) -CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above;

Z is selected from:

(1) hydrogen,

(2) C.sub.1-6 alkyl, and

(3) hydroxy, with the proviso that if Y is -O-, Z is other than hydroxy, or if Y is -CHR.sup.15 -, then Z and R.sup.15 are optionally joined together to form a double bond.

2. The method of claim 1 wherein the compound of formula I:

R.sup.2 and R.sup.3 are independently selected from the group consisting of:

(1) hydrogen,

(2) C.sub.1-6 alkyl,

(3) C.sub.2-6 alkenyl, and

(4) phenyl;

R.sup.6, R.sup.7 and R.sup.8 are independently selected from the group consisting of:

(1) hydrogen,

(2) C.sub.1-6 alkyl,

(3) fluoro,

(4) chloro,

(5) bromo,

(6) iodo, and

(7) -CF.sub.3 ;

R.sup.11, R.sup.12 and R.sup.13 are independently selected from the group consisting of:

(1) fluoro,

(2) chloro,

(3) bromo, and

(4) iodo;

A is unsubstituted C.sub.1-6 alkyl;

B is selected from the group consisting of: ##STR14## p is 0; X is selected from:

(a) -PO(OH)O.sup.-.M.sup.+, wherein M.sup.+ is a pharmaceutically acceptable monovalent counterion.

(b) -PO(O.sup.-).sub.2.2M.sup.+,

(c) -PO(O.sup.-).sub.2.D.sup.2+, wherein D.sup.2+ is a pharmaceutically acceptable divalent counterion,

(d) -CH(R.sup.4)-PO(OH)O.sup.-.M.sup.+, wherein R.sup.4 is hydrogen or methyl,

(e) -CH(R.sup.4)-PO(O.sup.-).sub.2.2M.sup.+, wherein R.sup.4 is hydrogen or methyl,

(f) -CH(R.sup.4)-PO(O.sup.-).sub.2.D.sup.2+, wherein R.sup.4 is hydrogen or methyl,

(i) -CO-CH.sub.2 CH.sub.2 -CO.sub.2.sup.-.M.sup.+,

(j) -CH(CH.sub.3)-O-CO-R.sup.5, wherein R.sup.5 is selected from the group consisting of: ##STR15## Y is -O-; Z is hydrogen or C.sub.1-4 alkyl.

3. The method of claim 1 wherein the compound of formula I:

Z is C.sub.1-4 alkyl.

4. The method of claim 1 wherein the compound of formula I:

Z is -CH.sub.3.

5. The method of claim 1 wherein the compound of formula I:

A is -CH.sub.2 - or -CH(CH.sub.3)-.

6. The method of claim 1 wherein the compound of formula I:

-B is selected from the group consisting of: ##STR16##

7. The method of claim 1 wherein the compound of formula I:

-A-B is selected from the group consisting of: ##STR17##

8. The method of claim 1 wherein the compound of formula I:

-A-B is selected from the group consisting of: ##STR18##

9. The method of claim 1 wherein the compound of formula I:

X is selected from the group consisting of:

(a) -PO(O.sup.-).sub.2.2M.sup.+, wherein M.sup.+ is a pharmaceutically acceptable monovalent counterion,

(b) -PO(O.sup.-).sub.2.2D.sup.2+, wherein D.sup.2+ is a pharmaceutically acceptable monovalent counterion,

(c) -CH(CH.sub.3)-O-CO-CH.sub.2 CH.sub.2 -NH.sub.3.sup.+. M.sup.-, and

(d) -CH(CH.sub.3)-O-CO-CH.sub.2 CH.sub.2 -NH.sub.2.sup.+ -(CH.sub.2 CH.sub.2 -OH).M.sup.-.

10. The method of claim 1 wherein the compound of formula I is of the structural formula II: ##STR19## or a pharmaceutically acceptable salt thereof, wherein R.sup.2, R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.11, R.sup.12, R.sup.13, A, B and Z are as defined in claim 1.

11. The method of claim 1 wherein the compound of formula I is of the structural formula III: ##STR20## or a pharmaceutically acceptable salt thereof, wherein R.sup.2, R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.11, R.sup.12, R.sup.13, A, B and Z are as defined in claim 1.

12. A method for the treatment or prevention of emesis in a mammal in need thereof which comprises the administration to the mammal of an effective amount of a compound which is selected from the group consisting of:

(1) 2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-3-(S)-phenyl-4-(3-(5-oxo-1H,4H-1 ,2,4-triazolo)-methyl)morpholine N-oxide;

(2) 2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-3-(S)-phenyl-4-(3-(4-(ethoxycarb onyloxy-1-ethyl)5-oxo-1 H-1,2,4-triazolo)-methyl)morpholine;

(3) 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)-phenyl)ethoxy)-3-(S)-(4-fluoro) )-phenyl-4-(3-(4-monophosphoryl-5-oxo-1 H-1,2,4-triazolo )-methyl)morpholine;

(4) 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)-phenyl)ethoxy)-3-(S)-(4-fluoro)-phe nyl-4-(3-(1-monophosphoryl-5-oxo-1 H-1,2,4-triazolo)-methyl)morpholine;

(5) 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)-phenyl)ethoxy)-3-(S)-(4-fluoro)-phe nyl-4-(3-(2-monophosphoryl-5-oxo-1 H-1,2,4-triazolo) methyl) morpholine;

(6) 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)-phenyl)ethoxy)-3-(S)-(4-fluoro)-phe nyl-4-(3-(5-oxyphosphoryl-1 H-1,2,4-triazolo)-methyl morpholine;

(7)2-(S)-(1-(R)-(3,5-bis(trifluoromethyl)-phenyl)ethoxy)-3-(S)-(4-fluoro)-p henyl-4-(3-(1-phosphoryl-5-oxo-4H-1,2,4-triazolo)-methyl)morpholine;

or a pharmaceutically acceptable salt thereof.

13. The method of claim 12 wherein the compound is present as the bis(N-methyl-D-glucamine) salt.

14. A method for the treatment or prevention of emesis in a mammal in need thereof which comprises the administration to the mammal of an effective amount of a compound which is selected from the group consisting of: ##STR21## wherein K.sup.+ is a pharmaceutically acceptable counterion.

15. The method of claim 14 wherein the compound K.sup.+ is N-methyl-D-glucamine.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
 NCE-1 Patent Challenge Dates 2024 - 2025
 Trigger-based marketing for the life sciences
 Get DrugPatentWatch Business Intelligence Reports at Amazon.com
 DrugChatter - AI-based answers to questions about drugs
 RxJam - Digital Marketing for Life Sciences
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group